Compare
Revvity, Inc. vs Bio-Rad Laboratories, Inc. vs Bruker Corp vs Illumina, Inc.
| Latest fiscal year | Revvity, Inc. RVTY | Bio-Rad Laboratories, Inc. BIO | Bruker Corp BRKR | Illumina, Inc. ILMN |
|---|---|---|---|---|
| Year ended | 2025-12-28 | 2025-12-31 | 2025-12-31 | 2025-12-28 |
| Revenue | $2.86B | $2.58B | $3.44B | $4.34B |
| Revenue growth (YoY) | +3.7% | +0.7% | +2.1% | -0.7% |
| Gross margin | n/a | 51.9% | 45.9% | 66.1% |
| Operating margin | 12.5% | 1.8% | 2.0% | 18.6% |
| Net margin | 8.4% | 29.4% | -0.2% | 19.6% |
| Net income | $241.20M | $759.90M | -$8.30M | $850.00M |
| EPS (Diluted) | $2.07 | $27.85 | -$0.15 | $5.45 |
| Operating cash flow | $582.93M | $532.20M | $134.10M | $1.08B |
| Free cash flow | $509.41M | $374.60M | $43.30M | $931.00M |
| Cash & equivalents | $919.86M | $529.80M | $298.80M | n/a |
| Total assets | $12.17B | $10.58B | $6.24B | $6.64B |
| Total liabilities | $4.92B | $3.12B | $3.73B | n/a |
| Shareholders' equity | $7.25B | $7.45B | $2.47B | $2.72B |
| Return on year-end equity | 3.3% | 10.2% | -0.3% | 31.2% |
| Shares outstanding | 112.28M | n/a | 152.14M | 153.00M |
Revenue, most recent five fiscal years
| Fiscal year | Revvity, Inc. | Bio-Rad Laboratories, Inc. | Bruker Corp | Illumina, Inc. |
|---|---|---|---|---|
| Latest | $2.86B Ended 2025-12-28 | $2.58B Ended 2025-12-31 | $3.44B Ended 2025-12-31 | $4.34B Ended 2025-12-28 |
| 1 year earlier | $2.76B Ended 2024-12-29 | $2.57B Ended 2024-12-31 | $3.37B Ended 2024-12-31 | $4.37B Ended 2024-12-29 |
| 2 years earlier | $2.75B Ended 2023-12-31 | $2.67B Ended 2023-12-31 | $2.96B Ended 2023-12-31 | $4.50B Ended 2023-12-31 |
| 3 years earlier | $3.31B Ended 2023-01-01 | $2.80B Ended 2022-12-31 | $2.53B Ended 2022-12-31 | $4.58B Ended 2023-01-01 |
| 4 years earlier | $3.83B Ended 2022-01-02 | $2.92B Ended 2021-12-31 | $2.42B Ended 2021-12-31 | $4.53B Ended 2022-01-02 |